Editorial: Innovative therapeutical approaches for hematological malignancies based on molecular targeted therapies

Current Pharmaceutical Design

Volumn 14, Issue 21, 2008, Pages 2022-

  Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLLYSOPHOSPHOLIPID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; ENZASTAURIN; MICRORNA; MONOCLONAL ANTIBODY; PERIFOSINE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN MDM2; PROTEIN P53; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANGIOGENESIS; B LYMPHOCYTE; BIOGENESIS; CANCER THERAPY; CELL MEMBRANE; EDITORIAL; GENE ACTIVATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; METASTASIS; MOLECULAR THERAPY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEMATOLOGIC NEOPLASMS; HUMANS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52949118818     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785294645     Document Type: Editorial

References (7)

1. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F. An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. Curr Pharm Des 2008; 14(21): 2023-2039.
2. Barbarotto E, Calin GA. Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies. Curr Pharm Des 2008; 14(21): 2040-2050.
3. Bernard MP, Bancos S, Sime PJ, Phipps RP. Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise. Curr Pharm Des 2008; 14(21): 2051-2060.
4. van Blitterswijk WJ, Verheij M. Anticancer Alkylphospholipids: Mechanisms of Action, Cellular, Sensitivity and Resistance, and Clinical Prospects. Curr Pharm Des 2008; 14(21): 2061-2074.
5. Mischiati C, Melloni E, Corallini F, Milani D, Bergamini C, Vaccarezza M. Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies. Curr Pharm. Des 2008; 14(21): 2075-2084.
6. Sancilio S, Grill V, Di Pietro R. A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies. Curr Pharm Des 2008; 14(21): 2085-2099.
7. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Hematological Malignancies. Curr Pharm Des 2008; 14(21): 2100-2110.